Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Inclusion Criteria: * Histologically or cytologically confirmed soft tissue sarcoma * Unresectable disease * Locally advanced or metastatic disease * The following tumor types are not allowed: * Embryonal and alveolar rhabdomyosarcoma * Gastrointestinal stromal tumor * Alveolar soft part sarcoma * Clear cell sarcoma * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan * No more than 1 prior therapy for sarcoma * No known brain metastases * ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% * ANC ≥ 1,500/µL * Platelet count ≥ 100,000/µL * Leukocytes ≥ 3,000/µL * Total bilirubin ≤ upper limit of normal(ULN) * AST and ALT ≤ 2.5 times ULN * Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min * Fasting serum glucose \< 120 mg/dL OR below ULN * LVEF ≥ 50% by MUGA scan * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after the last dose of anti-IGF-1R recombinant monoclonal antibody IMC-A12 * No history of allergic reactions attributed to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12 * No poorly controlled diabetes mellitus * Patients with a history of diabetes mellitus are eligible provided their blood glucose is within normal range and they are on a stable dietary or therapeutic regimen for this condition * No concurrent un…